Home > Insider Trading > Filing (0001104659-20-069570)

Filing Details

Accession Number:: 0001104659-20-069570
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-06-03 20:20:13
Reporting Period:: 2020-06-01

Accepted Time:: 2020-06-03 20:20:13
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1659323	Iterum Therapeutics Plc	ITRM	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1202793	Michael Powell	C/O Sofinnova Investments, Inc. 3000 Sand Hill Road, Bldg. 4, Suite 250 Menlo Park CA 94025	No	No	Yes	No
1245624	James Healy	C/O Sofinnova Investments, Inc. 3000 Sand Hill Road, Bldg. 4, Suite 250 Menlo Park CA 94025	No	No	Yes	No
1612133	Sofinnova Venture Partners Ix, L.p.	C/O Sofinnova Investments, Inc. 3000 Sand Hill Road, Bldg. 4, Suite 250 Menlo Park CA 94025	No	No	Yes	No
1612134	Sofinnova Management Ix, L.l.c.	C/O Sofinnova Investments, Inc. 3000 Sand Hill Road, Bldg. 4, Suite 250 Menlo Park CA 94025	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Disposition	2020-06-01	100,000	$1.69	1,626,514	No	4	S	Direct
Ordinary Shares	Disposition	2020-06-02	400,000	$1.61	1,226,514	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Footnotes

The price realized by the reporting person from the sales reported in Table I of this Form 4 is less than the market price of the Issuer's Ordinary Shares on the date of any purchase transaction that is potentially matchable during the previous six months. Thus, no short-swing profit is recoverable for purposes of Section 16(b).
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.69 to $1.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
The securities are held directly by Sofinnova Venture Partners IX, L.P. (the "Fund"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the "GP") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.58 to $1.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.